Tralokinumab

LEO Pharma's long-term extension study of Adbry (tralokinumab-ldrm) for atopic dermatitis showed sustained efficacy and safety over five years, with 92.9% of patients achieving a 75% reduction in Eczema Area and Severity Index and 66.7% achieving clear or almost clear skin.

Sun Pharma's Leqselvi 8 mg tablets showed significant scalp hair regrowth in severe alopecia areata patients. Adbry achieved EASI-75 in 92.9% and IGA 0/1 in 66.7% of AD patients. Joel Gelfand discussed complex psoriasis cases and phototherapy at Fall Clinical 2024. Ebglyss reduced eczema severity and itch, with 60% of prior dupilumab patients meeting key improvements. Aaron Farberg explored melanoma and cSCC prognostic tools and gene expression profiling. Chovatiya presented on chronic and eczema and early career controversies. Rocatinlimab affected SCORAD scores in atopic dermatitis patients.

Leo Pharma's Adbry (tralokinumab-ldrm) shows long-term safety and efficacy in atopic dermatitis, with 92.9% of patients achieving EASI-75 reduction and 66.7% achieving clear or almost clear skin at week 248. Adbry targets IL-13, driving inflammatory processes in atopic dermatitis, and has been FDA-approved since 2021, with expanded use in adolescents in 2023.

Final ECZTEND trial results show no new safety signals in adults and adolescents with moderate-to-severe AD treated with tralokinumab-ldrm for up to six years, with sustained efficacy and improved quality of life.

LEO Pharma's CEO, Christophe Bourdon, discusses the company's extensive presence at the 33rd EADV Congress, highlighting 5 late-breaking presentations and 23 scientific posters, the largest data collection shared by LEO Pharma at EADV. Bourdon emphasizes LEO Pharma's commitment to addressing unmet needs in dermatology, particularly chronic hand eczema, and the recent approval of delgocitinib in Europe and filing acceptance in the US. He also reflects on LEO Pharma's growth and innovation under his leadership, aiming to maintain and reinforce the company's leadership in medical dermatology.

Leo Pharma introduces an additional option for US patients using eczema treatment Adbry, a key driver of North American sales.

Eli Lilly’s Ebglyss (lebrikizumab) enters the U.S. atopic dermatitis market post FDA approval, competing with biologics like Dupixent and Adbry.

FDA approves Eli Lilly's Ebglyss (lebrikizumab) for moderate-to-severe atopic dermatitis, offering once-monthly dosing. Ebglyss targets IL-13, providing clear skin in 38% of patients at 16 weeks, compared to 12% with placebo. Common side effects include eye inflammation, injection site reactions, and shingles.

Despite declining use of Sanofi/Regeneron’s Dupixent due to competition from LEO’s Adbry, Pfizer’s Cibinqo, and AbbVie’s Rinvoq, the overall population receiving advanced treatments for atopic dermatitis is rising, according to Spherix Global Insights. Dermatologists estimate that two-fifths of adult atopic dermatitis patients now receive advanced systemic treatments, highlighting the demand for effective AD treatments. The potential approvals of Galderma’s nemolizumab and Eli Lilly’s lebrikizumab could further shift physician preferences, with nemolizumab expected to gain more adoption than lebrikizumab.